Analyst firms · Morgan Stanley · EVO

Morgan Stanley EVO price target and rating history

Evotec SE (EVO) · Health Care

Morgan Stanley rates Evotec SE (EVO) Equal-Weight with a $6 price target, as of its latest action on Jul 29, 2024. It has published 4 rating actions on EVO since August 2022, including 2 upgrades and 2 downgrades.

Current rating
Equal-Weight
Price target
$6
Median target, all firms
Too few
Actions on EVO
4

Morgan Stanley price target on EVO

$16$11$62023202420252026
Morgan Stanley price target on EVO, each point a stated target, August 2022 to July 2024.

Every Morgan Stanley rating on EVO

How other firms rate EVO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BerenbergHoldJul 16, 2026
TD CowenHold$2Jul 15, 2026
H.C. WainwrightBuy$7Apr 15, 2026

Questions about Morgan Stanley and EVO

What is Morgan Stanley's price target for EVO?
Morgan Stanley's latest stated price target for Evotec SE (EVO) is $6, from its action on Jul 29, 2024.
What is Morgan Stanley's rating on EVO?
Morgan Stanley rates EVO Equal-Weight, a neutral rating, as of Jul 29, 2024.
When did Morgan Stanley last change its view on EVO?
On Jul 29, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $15 to $6.

More EVO rating histories

All Morgan Stanley ratingsEVO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.